Commission will accept comments on recent workshop, eight identified weight-loss ad claims through Feb. 3. During Strategic Research Institute conference Dec. 9, Division of Advertising Practices Senior Staff Attorney Richard Cleland noted that after comment period closes, FTC will put together staff report with recommendations on whether eight claims are scientifically feasible, as well as suggestions on industry self-regulation, media screening of weight-loss ads. November workshop featured scientific panel that almost unanimously concluded eight weight-loss claims, such as "works for everyone," lack sufficient scientific support (1"The Tan Sheet" Nov. 25, 2002, p. 4)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The European Medicines Agency’s chief medical officer Steffen Thistrup argued that patients are able to understand the “complex regulatory and scientific issues” that the EMA committees discuss when they assess drugs.
Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.